eMedicine Specialties > Emergency Medicine > Trauma & Orthopedics

Back Pain, Mechanical: Treatment & Medication

Author: Debra G Perina, MD, Associate Professor, Director of Prehospital Care Division, Department of Emergency Medicine, University of Virginia Health Sciences Center
Contributor Information and Disclosures

Updated: Jul 16, 2009

Treatment

Prehospital Care

  • If the patient's back pain is from a traumatic injury, full spinal precautions using a long backboard for spinal immobilization should be used.
  • If no history of trauma is present, spinal precautions is not necessary, as the patient may experience significant exacerbation of pain by lying on a rigid board. If the patient is brought into the emergency department on a rigid board, they should be removed from the board at the first opportunity.
  • If a rigid board is necessary, the patient may be made more comfortable by supporting the lower extremities with a pillow or blanket.

Emergency Department Care

If new neurologic deficits are noted accompanied by bowel or bladder dysfunction one should suspect cauda equina syndrome. This is a true emergency, and emergency imaging is mandated. MRI is the preferred imaging modality in this situation. If cauda equina syndrome is strongly suspected, the practitioner should consider giving dexamethasone without delay to prevent further loss of neurologic function while pursuing confirmatory testing. 

Conservative therapy is the mainstay of treatment, as even those with true sciatica generally respond.14 Ultimately, only 2% of patients with sciatica and 4-6% of patients with true disc herniation require surgery. Conservative therapy traditionally includes the following:

  • Bed rest, once the cornerstone of treatment, is no longer widely recommended.
    • A growing body of evidence suggests that even brief bed rest is not necessary except in patients with true sciatica. In this case, the supine position decreases pressure on the spinal cord itself, and is useful for the first 2-3 days.
    • Early mobilization with gentle range of motion and strengthening exercises are recommended for patients with nonsciatic back pain.15
    • Early return to work on light duty or restricted activity lead to better long-term outcomes.
  • Pharmacologic therapy involves both anti-inflammatory medication and muscle relaxants.
    • Narcotics may be used initially to gain relief, but their long-term use is associated with increased functional impairment.
    • Steroids, while highly recommended by some practitioners, lack prospective confirmation of their value. Some physicians may prescribe a single burst or short course of oral steroids, which can be beneficial, particularly in those with a significant degree of inflammation.
    • Epidural steroid injection may also bring significant short-term relief, but this treatment is not without adverse effects and has not been shown to provide lasting benefit.16
  • Unless the patient is allergic to the medicine or it is otherwise contraindicated, severe low back pain can be improved significantly with a combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants.
  • Use of hot or cold compresses has never been proven scientifically to speed symptom resolution, but some patients may experience brief relief.
  • Gentle flexion/extension exercises are helpful.17,18
  • Spinal traction is ineffective.

Evidence-based clinical practice guidelines from the American Pain Society (APS) for patients with chronic low back pain describe the use of interventional diagnostic tests and therapies, surgeries, and interdisciplinary rehabilitation.19

  • Practice guidelines for nonradicular pain
    • Interdisciplinary rehabilitation emphasizing cognitive-behavioral approaches should be considered for patients who do not respond to usual interventions.
    • Provocative discography (injecting material into a disc nucleus in an attempt to reproduce the patient's typical pain) is not recommended.
    • Facet joint corticosteroid injection, prolotherapy (repeated injections of irritant material to stimulate an inflammatory response), and intradiscal corticosteroid injection are not recommended.
    • Persistent disabling symptoms and degenerative spinal changes should prompt discussion and shared decision-making regarding surgery or interdisciplinary rehabilitation (evidence is insufficient to weigh the risks and benefits of vertebral disc replacement in these patients).
  • Practice guidelines for persistent radiculopathy
    • For patients with herniated discs, the use of epidural steroid injection should be discussed.
    • For patients with herniated discs and disabling leg pain from spinal stenosis, surgical options should be discussed.
    • For patients with persistent pain after surgery, the risks and benefits of spinal cord stimulation should be discussed.

Consultations

  • ED consultation with a specialist is necessary for patients who present with acute cauda equina syndrome, demonstrate intractable pain, have evidence of a serious etiology (eg, epidural abscess, tumor), or where a social situation makes hospitalization necessary.
  • Whether orthopedic or neurosurgical consultation is chosen depends on local custom and resources.
  • Other medical consultation may be needed if the cause of back pain is not mechanical.

Medication

The goal of pharmacotherapy is to reduce pain and inflammation.

Nonsteroidal anti-inflammatory agents (NSAIDs)

NSAIDs are most commonly used to relieve mild to moderate pain. Although the effectiveness of NSAIDs tends to be patient specific, ibuprofen is usually the DOC for initial therapy. Other options include flurbiprofen, ketoprofen, and naproxen.


Ibuprofen (Ibuprin, Advil, Motrin)

DOC to treat mild to moderate pain if no contraindications exist.
Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Adult

600 mg PO tid

Pediatric

<6 months: Not established
6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid
>12 years: Administer as in adults

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Ketoprofen (Oruvail, Orudis, Actron)

For relief of mild to moderate pain and inflammation.
Small dosages initially are indicated in patients who are small or elderly and in those with renal or liver disease. Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response.

Adult

25-50 mg PO q6-8h prn; not to exceed 300 mg/d

Pediatric

<3 months: Not established
3 months to 12 years: 0.1–1 mg/kg PO q6-8h
>12 years: Administer as in adults

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy


Naproxen (Anaprox, Naprelan, and Naprosyn)

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis.

Adult

500 mg PO initial, followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug

Muscle relaxants

These agents reduce tonic somatic motor activity of the muscle.


Carisoprodol (Soma)

Short-acting medication that may have depressant effects at spinal cord level.
Skeletal muscle relaxants have modest short-term benefit as adjunctive therapy for nociceptive pain associated with muscle strains and, used intermittently, for diffuse and certain regional chronic pain syndromes. Long-term improvement over placebo has not been established.

Adult

350 mg PO tid/qid

Pediatric

Not established

Increases toxicity of alcohol, CNS depressants, MAO inhibitors, clindamycin, phenothiazines

Documented hypersensitivity; acute intermittent porphyria

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in renal and hepatic impairment


Cyclobenzaprine (Flexeril)

Skeletal muscle relaxant that acts centrally and reduces motor activity of tonic somatic origins influencing both alpha and gamma motor neurons.
Structurally related to tricyclic antidepressants and thus carries some of the same liabilities.

Adult

10 mg PO tid with a range of 20-40 mg/d in divided doses; not to exceed 60 mg/d

Pediatric

Not established

Coadministration with MAOIs and tricyclic antidepressants may increase toxicity; cyclobenzaprine may have additive effect when used concurrently with anticholinergics; effects of alcohol, CNS depressants, and barbiturates may be enhanced with cyclobenzaprine

Documented hypersensitivity; patients who have taken MAOIs within the last 14 d

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in angle-closure glaucoma, urinary hesitance

Analgesics

Pain control is essential to ensure patient comfort, to promote pulmonary toilet, and to aid physical therapy regimens. Many analgesics have sedating properties that benefit patients who have sustained injuries.


Acetaminophen (Tylenol, Panadol, Aspirin Free Anacin)

DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, in those with upper GI disease, or in those who are taking oral anticoagulants.

Adult

325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d

Pediatric

<12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d
>12 years: 325-650 mg PO q4h; not to exceed 5 doses/d

Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity

Documented hypersensitivity; known G-6-PD deficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Hepatotoxicity possible in chronic alcoholics following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose


Acetaminophen and codeine (Tylenol #3)

A drug combination indicated for the treatment of mild to moderate pain.

Adult

30-60 mg/dose based on codeine content PO q4-6h or 1-2 tabs q4h; not to exceed 12 tabs/d

Pediatric

0.5-1 mg/kg/dose based on codeine content PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen

Toxicity increases with CNS depressants or tricyclic antidepressants

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction


Hydrocodone bitartrate and acetaminophen (Vicodin ES)

A drug combination indicated for the relief of moderate to severe pain.

Adult

1-2 tab or cap PO q4-6h prn

Pediatric

<12 years: 10-15 mg/kg/dose acetaminophen q4-6h PO prn; not to exceed 2.6 g/d acetaminophen
>12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate in single dose; not to exceed 5 doses/d

Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants

Documented hypersensitivity; elevated intracranial pressure

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction

More on Back Pain, Mechanical

Overview: Back Pain, Mechanical
Differential Diagnoses & Workup: Back Pain, Mechanical
Treatment & Medication: Back Pain, Mechanical
Follow-up: Back Pain, Mechanical
References

References

  1. Kinkade S. Evaluation and treatment of acute low back pain. Am Fam Physician. Apr 15, 2007;74(8):1181-8. [Medline].

  2. Atlas SJ, Chang Y, Kammann E, Keller RB, Deyo RA, Singer DE. Long-term disability and return to work among patients who have a herniated lumbar disc: the effect of disability compensation. J Bone Joint Surg Am. Jan 2000;82(1):4-15. [Medline].

  3. de Inocencio J. Musculoskeletal pain in primary pediatric care: analysis of 1000 consecutive general pediatric clinic visits. Pediatrics. Dec 1998;102(6):E63. [Medline].

  4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain?. JAMA. Aug 12 1992;268(6):760-5. [Medline].

  5. Boden SD, Davis DO, Dina TS, Patronas NJ, Wiesel SW. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am. Mar 1990;72(3):403-8. [Medline].

  6. Hadjipaviou AG, Tzermiadianos MN, Bogduk N, Zindrick MR. The pathophysiology of disc degeneration: a critical review. J Bone Joint Surg Br. Oct 2008;90(10):1261-70. [Medline].

  7. van Tulder M, Koes B. Low back pain and sciatica (chronic). Clin Evid. Dec 2003;(10):1359-76. [Medline].

  8. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. Feb 1 2001;344(5):363-70. [Medline].

  9. Borenstein D. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr Opin Rheumatol. Mar 1996;8(2):124-9. [Medline].

  10. Marriott A, Newman NM, Gracovetsky SA, Richards MP, Asselin S. Improving the evaluation of benign low back pain. Spine. May 15 1999;24(10):952-60. [Medline].

  11. Frank AO, De Souza LH, McAuley JH, Sharma V, Main CJ. A cross-sectional survey of the clinical and psychological features of low back pain and consequent work handicap: use of the Quebec Task Force classification. Int J Clin Pract. Dec 2000;54(10):639-44. [Medline].

  12. Lurie JD. What diagnostic tests are useful for low back pain?. Best Pract Res Clin Rheumatol. Aug 2005;19(4):557-75. [Medline].

  13. Kuritzky L. Current management of acute musculoskeletal pain in the ambulatory care setting. Am J Ther. Nov-Dec 2008;Suppl 10:S7-11. [Medline].

  14. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine. Sep 15 1997;22(18):2128-56. [Medline].

  15. Cherkin D, Sherman KJ. Conceptualization and evaluation of an optimal healing environment for chronic low-back pain in primary care. J Altern Complement Med. 2004;10 Suppl 1:S171-8. [Medline].

  16. Nelson L, Aspegren D, Bova C. The use of epidural steroid injection and manipulation on patients with chronic low back pain. J Manipulative Physiol Ther. May 1997;20(4):263-6. [Medline].

  17. Moffett JK, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. BMJ. Jul 31 1999;319(7205):279-83. [Medline].

  18. [Best Evidence] Sertpoyraz F, Eyigor S, Karapolat H, Capaci K, Kirazli Y. Comparison of isokinetic exercise versus standard exercise training in patients with chronic low back pain: a randomized controlled study. Clin Rehabil. Mar 2009;23(3):238-47. [Medline].

  19. [Guideline] Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine. May 1 2009;34(10):1066-77. [Medline].

  20. Hodges P, van den Hoorn W, Dawson A, Cholewicki J. Changes in the mechanical properties of the trunk in low back pain may be associated with recurrence. J Biomech. Jan 5, 2009;42(1):61-6.

  21. Lotz JC. The biomechanics of prevention and treatment for low back pain: 2nd international workshop. Clin Biomech (Bristol, Avon). Mar 1999;14(3):220-3. [Medline].

  22. Coste J, Delecoeuillerie G, Cohen de Lara A, Le Parc JM, Paolaggi JB. Clinical course and prognostic factors in acute low back pain: an inception cohort study in primary care practice. BMJ. Feb 26 1994;308(6928):577-80. [Medline].

  23. Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ. Outcome of low back pain in general practice: a prospective study. BMJ. May 2 1998;316(7141):1356-9. [Medline].

  24. Harris IA, Young JM, Rae H, Jalaludin BB, Solomon MJ. Factors associated with back pain after physical injury: a survey of consecutive major trauma patients. Spine. Jun 15 2007;32(14):1561-5. [Medline].

  25. Panjabi MM. Clinical spinal instability and low back pain. J Electromyogr Kinesiol. Aug 2003;13(4):371-9. [Medline].

  26. Spector LR, Madigan L, Rhyne A, Darden B 2nd, Kim D. Cauda equina syndrome. J Am Acad Orthop Surg. Aug 2008;16(8):471-9. [Medline].

  27. Tauney PJW, Siegel CB, LaBan MM. Thoracic and lumbar pain syndromes. In: Tintinalli, et al, eds. Emergency Medicine: A Comprehensive Study Guide. 4th ed. 2000:1866-1873.

  28. van Poppel MN, Hooftman WE, Koes BW. An update of a systematic review of controlled clinical trials on the primary prevention of back pain at the workplace. Occup Med (Lond). Aug 2004;54(5):345-52. [Medline].

  29. Walsh MJ. Evaluation of orthopedic testing of the low back for nonspecific lower back pain. J Manipulative Physiol Ther. May 1998;21(4):232-6. [Medline].

Further Reading

Keywords

low back pain, mechanical low back pain, low back pain treatment, low back pain causes, musculoligamentous injury, classic nerve root syndrome, musculoskeletal pain syndrome, impingement syndrome, herniated disk, herniated disc, spinal degeneration, cauda equina syndrome, myofascial pain syndrome, fibromyalgia, osteomyelitis, sacroiliitis, spinal stenosis, degenerative joint disease, straight leg test

Contributor Information and Disclosures

Author

Debra G Perina, MD, Associate Professor, Director of Prehospital Care Division, Department of Emergency Medicine, University of Virginia Health Sciences Center
Debra G Perina, MD is a member of the following medical societies: American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, National Association of EMS Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Edward Bessman, MD, Chairman, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University
Edward Bessman, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Eric L Legome, MD, Chair, Department of Emergency Medicine, St Vincent's Hospital Manhattan; Associate Professor, Department of Emergency Medicine, New York Medical College
Eric L Legome, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.